7 completed. 6 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Completed 6 |
| Phase 1 | 1 | Completed 1 |
Follow GAT: new trials by email Literature Review of GAT trials Research Report on GAT
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Validation of iCare IC1000 Tonometer iCare IC1000, iCare IC200, GAT - Intraocular Pressure | Not applicable | Completed | Icare Finland Oy | 168 | 2025-10-21 | 2026-04-07 |
| Quick Measure Study for iCare ST500 and iCare IC200 iCare ST500, iCare IC200, GAT - Intraocular Pressure | Not applicable | Completed | Icare Finland Oy | 122 | 2025-08-28 | 2025-12-11 |
| Intraocular Pressure Data Collection With Tonometers iCare IC1000, iCare ST500, iCare IC200 - Intraocular Pressure | Not applicable | Completed | Icare Finland Oy | 151 | 2024-05-29 | 2025-04-30 |
| iCare ST500 Clinical Trial iCare ST500, GAT, iCare IC200 - Intraocular Pressure | Not applicable | Completed | Icare Finland Oy | 165 | 2023-06-05 | 2023-11-30 |
| MIRAA - Implementation of Intensive Rehabilitation of Aphasia and/or Apraxia of Speech in Swedish Healthcare MIRAA (Multimodal Intensive Rehabilitation of Aphasia and Apraxia of speech) - Aphasia, Apraxia of Speech | Not applicable | Completed | Karolinska Institutet | 25 | 2021-03-10 | 2023-03-09 |
| Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors First part: Gatipotuzumab and Tomuzotuximab; Second part: Gatipotuzumab and Tomuzotuximab or anti-EGFR antibody (Cetuximab, Panitumumab or Necitumumab) - Solid Tumor, Adult | Phase 1 | Completed | Glycotope GmbH | 50 | 2017-11-02 | 2021-07-12 |
| Juvenile Justice Translational Research on Interventions for Adolescents in the Legal System Core, Enhanced - Substance Use Disorders | Not applicable | Completed | Chestnut Health Systems | 839 | 2013-07-01 | 2019-07-23 |
Aphasia (1) · Apraxias (1) · Stroke (1) · Substance-Related Disorders (1)
Icare Finland Oy (4) · Chestnut Health Systems (1) · Glycotope GmbH (1) · Karolinska Institutet (1)
Canada (2) · United States (2) · Germany (1) · Italy (1) · Slovenia (1) · Spain (1) · Sweden (1)
Angela A Robertson, Ph.D. (1) · Carl G Leukefeld, Ph.D. (1) · Christy K Scott, Ph.D. (1) · Danica K Knight, Ph.D. (1) · Ellika Schalling, Ph.D, SLP (1) · Gail A Wasserman, Ph.D. (1) · Gene H Brody, Ph.D. (1) · Michael L Dennis, Ph.D. (1) · Ralph DiClemente, Ph.D. (1) · Sebastian Ochsenreither, Dr. med. (1) · Steven R Belenko, Ph.D. (1) · Tisha R Wiley, Ph.D. (1)
PMID 27130175, PMID 28132705, PMID 29654518, PMID 29713840, PMID 31202287, PMID 35397434, PMID 35751945, PMID 38548060, PMID 40616691
2017 (1), U01DA036158 (1), U01DA036176 (1), U01DA036221 (1), U01DA036224 (1), U01DA036225 (1), U01DA036226 (1), U01DA036233 (1)